JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target of $58.00, representing significant upside potential from the current price ...

JMP Securities updated its outlook on Affirm Holdings Inc. (NASDAQ: NASDAQ:AFRM), increasing the price target to $85 from the ...

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today and set a price ...

JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.

Mr. Leibel's departure, as stated in the company's SEC filing, is not due to any disagreements or disputes with the company's operations or practices. He will continue to serve as an employee until ...

The killing U.S. bettors made this NFL season could nudge legal sports betting on this year’s Super Bowl toward $2 billion in regulated action.

Even with its well-documented benefits, DoE is often underutilised, especially for solving specialised or constrained ...

AI is evolving rapidly with recent breakthroughs making it more accessible and efficient than ever. Smaller, cost-effective ...

We recently compiled a list of the 12 AI News Investors Probably Missed. In this article, we are going to take a look at ...

We recently compiled a list of the 10 AI Stocks to Watch Amid the DeepSeek Buzz. In this article, we are going to take a look ...

The web services and cybersecurity specialist's share price ended the day's trading up 10.7% amid the backdrop of a 0.8% gain ...

CrowdStrike Holdings was recently the Nasdaq's best-performing stock as it and other cybersecurity companies got a boost after Chinese artificial intelligence startup DeepSeek reported a cyberattack.